The Diagnostic Value of Hybrid PET/MR for Systemic Amyloidosis
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Listed as NCT04006223, this observational or N/A phase trial focuses on PET/MR and Systemic Amyloidosis and remains ongoing. Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, it has been updated 12 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Unknown
-
Aug 2025 — Sep 2025 [monthly]
Unknown
-
Mar 2025 — Aug 2025 [monthly]
Unknown
Status: Recruiting → Unknown
-
Sep 2024 — Mar 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
▶ Show 7 earlier versions
-
Mar 2023 — Jul 2024 [monthly]
Recruiting
-
May 2022 — Mar 2023 [monthly]
Recruiting
-
Nov 2021 — May 2022 [monthly]
Recruiting
-
Mar 2021 — Nov 2021 [monthly]
Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Recruiting
-
Oct 2020 — Jan 2021 [monthly]
Recruiting
-
Aug 2019 — Oct 2020 [monthly]
Recruiting
First recorded
Mar 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
For direct contact, visit the study record on ClinicalTrials.gov .